Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
The purpose of this study is to determine if the addition of tipifarnib to standard letrozole therapy leads to a better response to treatment for your cancer in comparison to letrozole plus a placebo. Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors (FTI). It blocks proteins that make cancer cells grow.
Epistemonikos ID: a26739d5ca28a9be198a793b99fa2baa61b52846
First added on: May 04, 2024